(Q37412304)

English

Phase I active immunotherapy with combination of two chimeric, human epidermal growth factor receptor 2, B-cell epitopes fused to a promiscuous T-cell epitope in patients with metastatic and/or recurrent solid tumors

scientific article published on 14 September 2009

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

20 August 2017

Phase I active immunotherapy with combination of two chimeric, human epidermal growth factor receptor 2, B-cell epitopes fused to a promiscuous T-cell epitope in patients with metastatic and/or recurrent solid tumors (English)

1 reference

Europe PubMed Central

20 August 2017

1 reference

based on heuristic

inferred from title

author name string

Pravin T P Kaumaya

1

1 reference

Europe PubMed Central

20 August 2017

Kevin Chu Foy

2

1 reference

Europe PubMed Central

20 August 2017

Joan Garrett

3

1 reference

Europe PubMed Central

20 August 2017

Sharad V Rawale

4

1 reference

Europe PubMed Central

20 August 2017

Daniele Vicari

5

1 reference

Europe PubMed Central

20 August 2017

Jennifer M Thurmond

6

1 reference

Europe PubMed Central

20 August 2017

Tammy Lamb

7

1 reference

Europe PubMed Central

20 August 2017

Aruna Mani

8

1 reference

Europe PubMed Central

20 August 2017

Yahaira Kane

9

1 reference

Europe PubMed Central

20 August 2017

Catherine R Balint

10

1 reference

Europe PubMed Central

20 August 2017

Donald Chalupa

11

1 reference

Europe PubMed Central

20 August 2017

Gregory A Otterson

12

1 reference

Europe PubMed Central

20 August 2017

Charles L Shapiro

13

1 reference

Europe PubMed Central

20 August 2017

Jeffrey M Fowler

14

1 reference

Europe PubMed Central

20 August 2017

Michael R Grever

15

1 reference

Europe PubMed Central

20 August 2017

Tanios S Bekaii-Saab

16

1 reference

Europe PubMed Central

20 August 2017

William E Carson

17

1 reference

Europe PubMed Central

20 August 2017

language of work or name

0 references

publication date

14 September 2009

1 reference

Europe PubMed Central

20 August 2017

Journal of Clinical Oncology

1 reference

Europe PubMed Central

20 August 2017

27

1 reference

Europe PubMed Central

20 August 2017

31

1 reference

Europe PubMed Central

20 August 2017

5270-5277

1 reference

Europe PubMed Central

20 August 2017

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2773479

6 September 2017

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2773479

6 September 2017

Immunogenic HER-2/neu peptides as tumor vaccines

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2773479

6 September 2017

Rational Peptide-based vaccine design for cancer immunotherapeutic applications

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2773479

6 September 2017

Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2773479

6 September 2017

Concordant morphologic and gene expression data show that a vaccine halts HER-2/neu preneoplastic lesions

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2773479

6 September 2017

Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2773479

6 September 2017

Challenges in the development of effective peptide vaccines for cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2773479

6 September 2017

Peptide vaccines for cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2773479

6 September 2017

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2773479

6 September 2017

Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2773479

6 September 2017

Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2773479

6 September 2017

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2773479

6 September 2017

p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2773479

6 September 2017

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2773479

6 September 2017

Prediction and identification of a T cell epitope in the fusion protein of measles virus immunodominant in mice and humans

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2773479

6 September 2017

Humanization of an anti-p185HER2 antibody for human cancer therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2773479

6 September 2017

Peptide vaccines of the HER-2/neu dimerization loop are effective in inhibiting mammary tumor growth in vivo

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2773479

14 September 2017

Novel engineered trastuzumab conformational epitopes demonstrate in vitro and in vivo antitumor properties against HER-2/neu

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2773479

14 September 2017

The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2773479

14 September 2017

Prevention of mammary tumors with a chimeric HER-2 B-cell epitope peptide vaccine

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2773479

28 September 2017

Cytotoxic T cells isolated from ovarian malignant ascites recognize a peptide derived from the HER-2/neu proto-oncogene

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2773479

26 June 2018

Early role of CD4+ Th1 cells and antibodies in HER-2 adenovirus vaccine protection against autochthonous mammary carcinomas.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2773479

2 September 2018

Endogenous anti-HER2 antibodies block HER2 phosphorylation and signaling through extracellular signal-regulated kinase.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2773479

2 September 2018

Immunoprevention of mammary carcinoma in HER-2/neu transgenic mice is IFN-gamma and B cell dependent

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2773479

2 September 2018

Electroporated DNA vaccine clears away multifocal mammary carcinomas in her-2/neu transgenic mice.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2773479

2 September 2018

Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2773479

2 September 2018

Peptide-based, but not whole protein, vaccines elicit immunity to HER-2/neu, oncogenic self-protein.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2773479

2 September 2018

Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2773479

2 September 2018

High-titer HER-2/neu protein-specific antibody can be detected in patients with early-stage breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/19752336

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical trial results of a HER2/neu (E75) vaccine to prevent recurrence in high-risk breast cancer patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/19752336

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines

1 reference

https://pubmed.ncbi.nlm.nih.gov/19752336

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A chimeric multi-human epidermal growth factor receptor-2 B cell epitope peptide vaccine mediates superior antitumor responses

1 reference

https://pubmed.ncbi.nlm.nih.gov/19752336

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

HER2/neu-derived peptides are shared antigens among human non-small cell lung cancer and ovarian cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/19752336

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine

1 reference

https://pubmed.ncbi.nlm.nih.gov/19752336

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1200/JCO.2009.22.3883

1 reference

Europe PubMed Central

20 August 2017

1 reference

Europe PubMed Central

20 August 2017

1 reference

Europe PubMed Central

20 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37412304&oldid=1704981089"